Yi Xiao-Ming, Zhou Wen-Quan
Department of Urology, Nanjing University, School of Medicine/ Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
Zhonghua Nan Ke Xue. 2010 Jul;16(7):635-41.
Prostate cancer is one of the most common malignant tumors in males, and its etiology and pathogenesis remain unclear. Epigenesis is involved in prostate cancer at all stages of the process, and closely related with its growth and metastasis. DNA methylation and histone modification are the most important manifestations of epigenetics in prostate cancer. The mechanisms of carcinogenesis of DNA methylation include whole-genome hypomethylation, aberrant local hypermethylation of promoters and genomic instability. DNA methylation is closely related to the process of prostate cancer, as in DNA damage repair, hormone response, tumor cell invasion/metastasis, cell cycle regulation, and so on. Histone modification causes corresponding changes in chromosome structure and the level of gene transcription, and it may affect the cycle, differentiation and apoptosis of cells, resulting in prostate cancer. Some therapies have been developed targeting the epigenetic changes in prostate cancer, including DNA methyltransferases and histone deacetylase inhibitors, and have achieved certain desirable results.
前列腺癌是男性最常见的恶性肿瘤之一,其病因和发病机制尚不清楚。表观遗传学参与前列腺癌发生发展的各个阶段,与其生长和转移密切相关。DNA甲基化和组蛋白修饰是前列腺癌表观遗传学最重要的表现形式。DNA甲基化的致癌机制包括全基因组低甲基化、启动子异常局部高甲基化和基因组不稳定。DNA甲基化与前列腺癌的发生过程密切相关,如在DNA损伤修复、激素反应、肿瘤细胞侵袭/转移、细胞周期调控等方面。组蛋白修饰会引起染色体结构和基因转录水平的相应变化,可能影响细胞的周期、分化和凋亡,从而导致前列腺癌。目前已经开发了一些针对前列腺癌表观遗传变化的治疗方法,包括DNA甲基转移酶和组蛋白去乙酰化酶抑制剂,并取得了一定的理想效果。